Clinical Trial Update: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating mirvetuximab soravtansine in combination with pembrolizumab for endometrial cancer has posted results (as of May 15, 2025).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Mirvetuximab soravtansine (IMGN853) (mirvetuximab soravtansine)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Endometrial Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-15